Literature DB >> 2535213

Blood pressure as a risk factor for cardiovascular disease. The Framingham Study--30 years of follow-up.

J Stokes1, W B Kannel, P A Wolf, R B D'Agostino, L A Cupples.   

Abstract

Data from 30 years of follow-up of the original Framingham Study cohort of 5,070 men and women aged 30-62 years who were first examined during the period 1948-1952 and who were free of cardiovascular disease reveal that blood pressure is a strong and consistent predictor of the development of coronary heart disease, stroke, transient ischemic attack, and congestive heart failure. Other factors related to blood pressure like obesity, left ventricular hypertrophy as demonstrated on electrocardiograms, and heart enlargement as shown by x-ray radiography made several selective additional independent contributions to risk; heart enlargement by x-ray radiography was the best predictor of congestive heart failure.

Entities:  

Mesh:

Year:  1989        PMID: 2535213     DOI: 10.1161/01.hyp.13.5_suppl.i13

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  58 in total

Review 1.  Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.

Authors:  A Markham; K L Goa
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Associations between age, cohort, and urbanization with SBP and DBP in China: a population-based study across 18 years.

Authors:  Samantha M Attard; Amy H Herring; Bing Zhang; Shufa Du; Barry M Popkin; Penny Gordon-Larsen
Journal:  J Hypertens       Date:  2015-05       Impact factor: 4.844

3.  Graded associations between cardiorespiratory fitness, fatness, and blood pressure in children and adolescents.

Authors:  L Klasson-Heggebø; L B Andersen; A H Wennlöf; L B Sardinha; M Harro; K Froberg; S A Anderssen
Journal:  Br J Sports Med       Date:  2006-01       Impact factor: 13.800

4.  Effect of frequent or extended hemodialysis on cardiovascular parameters: a meta-analysis.

Authors:  Paweena Susantitaphong; Ioannis Koulouridis; Ethan M Balk; Nicolaos E Madias; Bertrand L Jaber
Journal:  Am J Kidney Dis       Date:  2012-02-25       Impact factor: 8.860

5.  Revised Reference Values for Potassium Intake.

Authors:  Daniela Strohm; Sabine Ellinger; Eva Leschik-Bonnet; Friederike Maretzke; Helmut Heseker
Journal:  Ann Nutr Metab       Date:  2017-08-11       Impact factor: 3.374

Review 6.  Cardiac target organ damage in hypertension: insights from epidemiology.

Authors:  Patrick R Lawler; Pranoti Hiremath; Susan Cheng
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 7.  Essential hypertension and risk of nephropathy: a reappraisal.

Authors:  Mariana Murea; Barry I Freedman
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-05       Impact factor: 2.894

8.  Relationship between CYP17A1 Genetic Polymorphism and Essential Hypertension in a Chinese Population.

Authors:  Chuan-Fang Dai; Xiang Xie; Yi-Tong Ma; Yi-Ning Yang; Xiao-Mei Li; Zhen-Yan Fu; Fen Liu; Bang-Dang Chen; Min-Tao Gai
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

9.  Rare Exome Sequence Variants in CLCN6 Reduce Blood Pressure Levels and Hypertension Risk.

Authors:  Bing Yu; Sara L Pulit; Shih-Jen Hwang; Jennifer A Brody; Najaf Amin; Paul L Auer; Joshua C Bis; Eric Boerwinkle; Gregory L Burke; Aravinda Chakravarti; Adolfo Correa; Albert W Dreisbach; Oscar H Franco; Georg B Ehret; Nora Franceschini; Albert Hofman; Dan-Yu Lin; Ginger A Metcalf; Solomon K Musani; Donna Muzny; Walter Palmas; Leslie Raffel; Alex Reiner; Ken Rice; Jerome I Rotter; Narayanan Veeraraghavan; Ervin Fox; Xiuqing Guo; Kari E North; Richard A Gibbs; Cornelia M van Duijn; Bruce M Psaty; Daniel Levy; Christopher Newton-Cheh; Alanna C Morrison
Journal:  Circ Cardiovasc Genet       Date:  2015-12-11

Review 10.  Exercise and mild essential hypertension. Recommendations for adults.

Authors:  N F Gordon; C B Scott; W J Wilkinson; J J Duncan; S N Blair
Journal:  Sports Med       Date:  1990-12       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.